Celularity (NASDAQ:CELU) Posts Earnings Results

Celularity (NASDAQ:CELU) issued its quarterly earnings results on Tuesday. The company reported $0.02 earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $5.43 million for the quarter.

Celularity Stock Down 17.9%

CELU stock traded down $0.23 during midday trading on Wednesday, reaching $1.03. The company’s stock had a trading volume of 192,807 shares, compared to its average volume of 1,331,787. Celularity has a 52 week low of $0.56 and a 52 week high of $2.55. The stock has a market cap of $33.59 million, a PE ratio of -0.38 and a beta of 0.77. The business’s 50-day simple moving average is $1.31 and its 200-day simple moving average is $1.03.

Institutional Trading of Celularity

A hedge fund recently bought a new stake in Celularity stock. C V Starr & Co. Inc. purchased a new position in Celularity, Inc. (NASDAQ:CELU) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity comprises approximately 0.8% of C V Starr & Co. Inc.’s investment portfolio, making the stock its 4th largest position. C V Starr & Co. Inc. owned 2.64% of Celularity at the end of the most recent quarter. Hedge funds and other institutional investors own 19.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company has an average rating of “Sell”.

About Celularity

Celularity, Inc is a biotechnology company focused on developing cell therapies and biomaterial products derived from human placental tissue. The company’s platform is designed to use the placenta as a scalable source of allogeneic cells and biomaterials for applications in oncology, immune-mediated diseases, infectious diseases and tissue repair.

Celularity’s development pipeline has included placental-derived natural killer cell programs, including CYNK-001, which has been evaluated for potential use in hematologic cancers and other diseases.